Algorithm predicts speech outcomes after cochlear implant

An algorithm developed by researchers at the Chinese University of Hong Kong has accurately predicted speech improvement in children who use cochlear implants (CIs). Findings were published in the Proceedings of the National Academy of Sciences of the United States of America.

This study described how the algorithm could improve personalized therapy for children with CIs to improve language development. Led by Gangyi Feng, PhD, from the Chinese University of Hong Kong, a team of researchers collected data using pre-surgical magnetic resonance images of pediatric CI patients to predict the variability in perceived speech improvement.

A machine learning model, trained on information of neuroanatomical networks affected or unaffected by auditory deprivation, was evaluated in comparisons of CI patients and a control group. Results showed the algorithm was most accurate, specific and sensitive for patient classification. It was precise in prediction when the region of the brain being evaluation was unaffected by auditory deprivation.

“These findings suggest that brain areas unaffected by auditory deprivation are critical to developing closer to typical speech outcomes," wrote Feng and colleagues. "Moreover, they suggest that determination of the type of neural reorganization caused by auditory deprivation before implantation is valuable for predicting post-CI language outcomes for young children."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.